Archive

Neovasc’s Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference

Posted on September 30, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, Sept. 30, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Neovasc Announces Changes to its Board of Directors

Posted on September 16, 2019
in
by

Norman Radow, Managing Partner at Strul Medical Group, Joins Company's Board NASDAQ, TSX: NVCN VANCOUVER, Sept. 16, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the...

Read More

The European Society of Cardiology Includes Neovasc Reducer™ for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes

Posted on September 3, 2019
in
by

Announcement Made at European Society of Cardiology Congress 2019 in Paris, France NASDAQ, TSX: NVCN VANCOUVER, Sept. 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in...

Read More

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Posted on August 22, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, Aug. 22, 2019 /CNW/ - ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market...

Read More

Neovasc Announces Second Quarter 2019 Financial Results

Posted on August 7, 2019
in
by

NASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the "Reducer") for CCS class IV patients and to meet for another Sprint discussion Closed Private Placement of Convertible Debt and Common Shares for Gross Proceeds of...

Read More

Neovasc to Attend Canaccord Genuity 39th Annual Growth Conference

Posted on August 5, 2019
in
by

Presentation Scheduled for 11:30 am Eastern Time on August 8th NASDAQ, TSX: NVCN VANCOUVER, Aug. 5, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development...

Read More